A topical sweaty armpit wipe was approved by the US Food and Drug Administration on Friday and provides people with a mild remedy for an often-anxiety-causing condition.
The company that produces the drug Dermira announced that its drug Qbrexza is the first of its kind to be approved by the FDA to reduce excessive sweating in the armpits. It is designed to prevent excessive sweating, a common condition that can embarrass people and harm their social lives. The drug is administered in a cloth that can be rubbed over the skin daily to block sweat gland activation. It will be available in stores in October.
The manufacturer Dermira Inc. declined to publish the award, The Associated Press reported.
Side effects of Qbrexza include blurred vision, constipation, burning and itchy skin, head and sore throat and dry mouth, eyes and skin.
In a study, 53 percent of patients said Qbrexza reduced sweat production by about half, compared to 28 percent in a peer group with a non-medicated towel, the pharmaceutical company reported
The pharmaceutical company worked with dermatologists and the FDA together during the development phase and talked with the people who lived with excessive sweating to understand their condition and find a solution. "We hope Qbrexza will not only bring the clinical benefits that these patients have sought, but also help reduce the overall burden on their lives," said Tom Wiggans, Chairman and Chief Executive Officer of Dermira.